IL105079A - Compositions for the treatment of fibrotic disorders - Google Patents
Compositions for the treatment of fibrotic disordersInfo
- Publication number
- IL105079A IL105079A IL105079A IL10507993A IL105079A IL 105079 A IL105079 A IL 105079A IL 105079 A IL105079 A IL 105079A IL 10507993 A IL10507993 A IL 10507993A IL 105079 A IL105079 A IL 105079A
- Authority
- IL
- Israel
- Prior art keywords
- phosphate
- mannose
- wound
- composition according
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 230000003176 fibrotic effect Effects 0.000 title claims abstract description 8
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 27
- 239000010452 phosphate Substances 0.000 claims abstract description 20
- 230000029663 wound healing Effects 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 60
- 206010052428 Wound Diseases 0.000 claims description 58
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 8
- 230000037390 scarring Effects 0.000 claims description 8
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NDVRKEKNSBMTAX-MVNLRXSJSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O NDVRKEKNSBMTAX-MVNLRXSJSA-N 0.000 abstract description 24
- 230000036573 scar formation Effects 0.000 abstract 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 30
- 230000000694 effects Effects 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 13
- 230000035876 healing Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- 235000021317 phosphate Nutrition 0.000 description 8
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 4
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 3
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- -1 mannose-6-phosphate Chemical class 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- HXXFSFRBOHSIMQ-UHFFFAOYSA-N [3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound OCC1OC(OP(O)(O)=O)C(O)C(O)C1O HXXFSFRBOHSIMQ-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- HXXFSFRBOHSIMQ-RWOPYEJCSA-L alpha-D-mannose 1-phosphate(2-) Chemical compound OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-RWOPYEJCSA-L 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929205800A GB9205800D0 (en) | 1992-03-17 | 1992-03-17 | Treatment of fibrotic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL105079A0 IL105079A0 (en) | 1993-07-08 |
| IL105079A true IL105079A (en) | 1998-06-15 |
Family
ID=10712310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL105079A IL105079A (en) | 1992-03-17 | 1993-03-16 | Compositions for the treatment of fibrotic disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5520926A (de) |
| EP (1) | EP0728006B1 (de) |
| JP (1) | JP3930556B2 (de) |
| AT (1) | ATE196847T1 (de) |
| AU (1) | AU667887B2 (de) |
| CA (1) | CA2130805C (de) |
| DE (1) | DE69329559T2 (de) |
| DK (1) | DK0728006T3 (de) |
| ES (1) | ES2151903T3 (de) |
| GB (2) | GB9205800D0 (de) |
| GR (1) | GR3035117T3 (de) |
| IL (1) | IL105079A (de) |
| NO (1) | NO306808B1 (de) |
| NZ (1) | NZ249915A (de) |
| PT (1) | PT728006E (de) |
| SG (1) | SG49899A1 (de) |
| WO (1) | WO1993018777A1 (de) |
| ZA (1) | ZA931869B (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| SE9403137D0 (sv) * | 1994-09-20 | 1994-09-20 | Perstorp Ab | Derivatives of carbohydrates and compositions containing them |
| US6566339B1 (en) | 1995-08-04 | 2003-05-20 | Renovo Limited | Pharmaceutical composition |
| GB9516012D0 (en) * | 1995-08-04 | 1995-10-04 | Univ Manchester | Pharmaceutical composition |
| GB2306481A (en) * | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US6093388A (en) * | 1996-08-12 | 2000-07-25 | Btg International Limited | Mannose-6-phosphate composition and its use in treating fibrotic disorders |
| GB9616896D0 (en) * | 1996-08-12 | 1996-09-25 | British Tech Group | Pharmaceutical compositions |
| DE19758059C2 (de) * | 1997-12-29 | 2001-10-04 | Thorsten Marquardt | Verwendung von Mannose zur Bekämpfung der Proteinverlust-Enteropathie |
| WO2002030432A1 (en) * | 2000-06-23 | 2002-04-18 | Cambridgemed, Inc | Agent for reduction of scar formation by using wound alkalinization |
| US20020082222A1 (en) * | 2000-11-30 | 2002-06-27 | Shapira Nathan Andrew | Treatments for neurogenetic disorders, impulse control disorder, and wound healing |
| US20030031689A1 (en) * | 2001-08-09 | 2003-02-13 | Thomas Mammone | Method of skin exfoliation |
| US6822033B2 (en) | 2001-11-19 | 2004-11-23 | United States Gypsum Company | Compositions and methods for treating set gypsum |
| AU2003209308A1 (en) * | 2002-01-22 | 2003-09-02 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection |
| BR0309890A (pt) * | 2002-05-09 | 2005-05-10 | Medigenes | Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação |
| GB0217136D0 (en) | 2002-07-24 | 2002-09-04 | Renovo Ltd | Wound healing & treatment of fibrosis |
| KR100492913B1 (ko) * | 2002-08-23 | 2005-06-03 | 주식회사 태평양 | 피부 감작 및 자극을 완화하는 피부 외용제 조성물 |
| US20050136126A1 (en) * | 2003-03-17 | 2005-06-23 | Cambridgemed, Inc. | Agent for reduction of scar formation by using wound alkalinization |
| JP4634027B2 (ja) * | 2003-05-16 | 2011-02-16 | 花王株式会社 | ビタミンｄ様活性代替用剤 |
| US7276486B2 (en) * | 2004-03-15 | 2007-10-02 | Kimberly-Clark Worldwide, Inc. | Compositions for vaginal treatment |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| JP5481028B2 (ja) * | 2004-10-13 | 2014-04-23 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | ウイルス関連リンパ増殖性障害を処置または予防するための方法 |
| US20070048391A1 (en) * | 2005-08-23 | 2007-03-01 | Cambridgemed, Inc. | Composition for reduction of scar formation on wound scar |
| US7323184B2 (en) * | 2005-08-22 | 2008-01-29 | Healagenics, Inc. | Compositions and methods for the treatment of wounds and the reduction of scar formation |
| EP1948675B1 (de) | 2005-10-25 | 2014-07-30 | The Johns Hopkins University | Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen |
| US8454952B2 (en) | 2006-03-13 | 2013-06-04 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
| DK2083863T3 (da) | 2006-10-03 | 2015-06-22 | Genzyme Corp | Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi |
| US8070895B2 (en) | 2007-02-12 | 2011-12-06 | United States Gypsum Company | Water resistant cementitious article and method for preparing same |
| US8329308B2 (en) | 2009-03-31 | 2012-12-11 | United States Gypsum Company | Cementitious article and method for preparing the same |
| GB0910078D0 (en) | 2009-06-11 | 2009-07-22 | Renovo Ltd | Uses of mannose-6-phosphate |
| GB0916333D0 (en) | 2009-09-17 | 2009-10-28 | Renovo Ltd | Improvement of tendon repair |
| GB0916334D0 (en) * | 2009-09-17 | 2009-10-28 | Renovo Ltd | Inhibition of tendon adhesions |
| ME02464B (de) | 2010-03-12 | 2017-02-20 | Genzyme Corp | Kombinationstherapie zur Behandlung von Brustkrebs |
| WO2012087434A2 (en) * | 2010-11-05 | 2012-06-28 | Healthypharma, Llc | Use of phosphoric acid |
| CA2823154A1 (en) | 2010-12-27 | 2012-07-05 | Lsip, Llc | Ips cells and method for generating same |
| US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
| WO2013062544A1 (en) | 2011-10-26 | 2013-05-02 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| EP2799537B1 (de) | 2011-12-28 | 2021-09-22 | Kyoto Prefectural Public University Corporation | Normalisierung der züchtung von hornhautendothelzellen |
| CA2927898C (en) | 2013-10-31 | 2021-11-16 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
| EP4490353A4 (de) * | 2022-03-08 | 2026-01-14 | Univ Of Mississippi Medical Center | Artikel und verfahren für verbesserte gewebeheilung |
| CN115260256A (zh) * | 2022-07-22 | 2022-11-01 | 河南中医药大学 | 一种甘露糖磷酸化衍生物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756953A (fr) * | 1969-10-02 | 1971-04-01 | Merck & Co Inc | Potentialisation d'antibiotiques |
| JPS5631156B2 (de) * | 1973-09-25 | 1981-07-20 | ||
| IT1170618B (it) * | 1981-01-13 | 1987-06-03 | Foscama Biomed Chim Farma | Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati |
| US4703040A (en) * | 1985-04-03 | 1987-10-27 | Markov Angel K | Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP) |
| ATE78166T1 (de) * | 1985-10-22 | 1992-08-15 | Silvetti Anthony N | Monosaccharide enthaltende zusammensetzung zum heilen von wunden. |
| US4889844A (en) * | 1985-10-22 | 1989-12-26 | Silvetti Sr Anthony N | Fructose containing wound healing preparation |
| AU607690B2 (en) * | 1985-12-24 | 1991-03-14 | Marion Laboratories, Inc. | Use of synthetic sulfated saccharides to enhance wound healing |
| JPS62243675A (ja) * | 1986-04-15 | 1987-10-24 | Kao Corp | ｐＨ緩衝法 |
| ATE139699T1 (de) * | 1988-08-19 | 1996-07-15 | Univ Australian | Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel |
| GB8917414D0 (en) * | 1989-07-29 | 1989-09-13 | Translift Material Handling | Narrow aisle lift truck |
| WO1991004748A1 (en) * | 1989-09-29 | 1991-04-18 | La Jolla Cancer Research Foundation | INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX |
| SE8904354D0 (sv) * | 1989-12-21 | 1989-12-21 | Matti Siren | A pharmaceutical composition |
| GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| JPH0558868A (ja) * | 1991-08-27 | 1993-03-09 | Kao Corp | 親水性紫外線吸収剤及びこれを含有する化粧料 |
| WO1993019783A1 (en) * | 1992-04-01 | 1993-10-14 | The Whittier Institute For Diabetes And Endocrinology | Methods of inhibiting or enhancing scar formation in the cns |
| JPH09155319A (ja) * | 1995-12-13 | 1997-06-17 | Takeo Tsutsui | 重金属含有焼却灰等、シュレッダーダストの無公害化処理方法および再利用材の製造方法 |
-
1992
- 1992-03-17 GB GB929205800A patent/GB9205800D0/en active Pending
-
1993
- 1993-03-16 EP EP93906680A patent/EP0728006B1/de not_active Expired - Lifetime
- 1993-03-16 GB GB9305344A patent/GB2265310B/en not_active Expired - Lifetime
- 1993-03-16 AT AT93906680T patent/ATE196847T1/de active
- 1993-03-16 SG SG1996008660A patent/SG49899A1/en unknown
- 1993-03-16 CA CA002130805A patent/CA2130805C/en not_active Expired - Lifetime
- 1993-03-16 DE DE69329559T patent/DE69329559T2/de not_active Expired - Lifetime
- 1993-03-16 WO PCT/GB1993/000541 patent/WO1993018777A1/en not_active Ceased
- 1993-03-16 US US08/290,939 patent/US5520926A/en not_active Expired - Lifetime
- 1993-03-16 DK DK93906680T patent/DK0728006T3/da active
- 1993-03-16 PT PT93906680T patent/PT728006E/pt unknown
- 1993-03-16 JP JP51635793A patent/JP3930556B2/ja not_active Expired - Lifetime
- 1993-03-16 ZA ZA931869A patent/ZA931869B/xx unknown
- 1993-03-16 ES ES93906680T patent/ES2151903T3/es not_active Expired - Lifetime
- 1993-03-16 NZ NZ249915A patent/NZ249915A/en not_active IP Right Cessation
- 1993-03-16 IL IL105079A patent/IL105079A/en not_active IP Right Cessation
- 1993-03-16 AU AU37590/93A patent/AU667887B2/en not_active Expired
-
1994
- 1994-09-16 NO NO943451A patent/NO306808B1/no not_active IP Right Cessation
-
2000
- 2000-12-19 GR GR20000402805T patent/GR3035117T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT728006E (pt) | 2001-04-30 |
| SG49899A1 (en) | 1998-06-15 |
| DE69329559D1 (de) | 2000-11-16 |
| ES2151903T3 (es) | 2001-01-16 |
| GB9205800D0 (en) | 1992-04-29 |
| IL105079A0 (en) | 1993-07-08 |
| GB9305344D0 (en) | 1993-05-05 |
| NO943451D0 (no) | 1994-09-16 |
| AU667887B2 (en) | 1996-04-18 |
| NO943451L (no) | 1994-09-16 |
| AU3759093A (en) | 1993-10-21 |
| GR3035117T3 (en) | 2001-03-30 |
| NO306808B1 (no) | 1999-12-27 |
| CA2130805C (en) | 2003-06-24 |
| CA2130805A1 (en) | 1993-09-30 |
| EP0728006B1 (de) | 2000-10-11 |
| EP0728006A1 (de) | 1996-08-28 |
| ZA931869B (en) | 1994-09-16 |
| ATE196847T1 (de) | 2000-10-15 |
| WO1993018777A1 (en) | 1993-09-30 |
| NZ249915A (en) | 1996-08-27 |
| JPH07504909A (ja) | 1995-06-01 |
| GB2265310B (en) | 1996-09-25 |
| DE69329559T2 (de) | 2001-05-31 |
| DK0728006T3 (da) | 2000-10-30 |
| US5520926A (en) | 1996-05-28 |
| JP3930556B2 (ja) | 2007-06-13 |
| GB2265310A (en) | 1993-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2130805C (en) | Use of mannose phosphates for the treatment of fibrotic disorders | |
| CA2387247C (en) | Use of neutralizing agents to growth factors for reducing wound scarring | |
| EP0646012B1 (de) | WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3 | |
| US4760051A (en) | Use of GHL-Cu as a wound-healing and anti-inflammatory agent | |
| US5015631A (en) | Repairing agent for cells and tissues | |
| US5384308A (en) | Composition and method for enhancing wound healing | |
| JP2008239625A (ja) | 医薬組成物 | |
| US20070154448A1 (en) | Methods and compositions using Substance P to promote wound healing | |
| JPH09510967A (ja) | 創傷の治癒 | |
| US6566339B1 (en) | Pharmaceutical composition | |
| KR100249136B1 (ko) | 섬유증 질환의 치료방법 | |
| GB2299025A (en) | Formulations of mannose phosphates useful in the treatment of fibrotic disorders | |
| US20080194478A1 (en) | Wound healing agent and composition | |
| AU751118B2 (en) | Pharmaceutical composition | |
| HK1053264B (en) | Phosphonate analogues of mannose-6-phosphate and their use in the treatment of wounds and fibrotic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |